Ionis Pharmaceuticals INC: directors' dealings · United States · SEC (Form 4)

About Ionis Pharmaceuticals INC

Ionis Pharmaceuticals, Inc. (ticker: IONS) is a U.S.-listed biopharmaceutical company traded on the Nasdaq in the United States. Headquartered in Carlsbad, California, and founded in 1989, Ionis is widely regarded as one of the pioneers of antisense technology and RNA-targeted medicines. Its business model now combines an emerging wholly owned commercial platform with a substantial base of partnered programs and royalty revenue, giving the company a distinctive profile in the mid-cap biotechnology universe. Ionis built its reputation by advancing oligonucleotide-based therapeutics for genetically driven and otherwise hard-to-treat diseases. The company’s core scientific edge is its proprietary RNA-targeted drug discovery platform, which is designed to modulate disease-causing proteins by acting upstream at the RNA level. This platform has produced a deep pipeline and a track record of important regulatory and commercial firsts. Ionis now markets several medicines directly or through partners, including TRYNGOLZA (olezarsen), approved for familial chylomicronemia syndrome; DAWNZERA (donidalorsen), approved for hereditary angioedema prophylaxis; and WAINUA (eplontersen), approved for hereditary transthyretin-mediated amyloidosis with polyneuropathy. It also receives royalties from partnered products such as SPINRAZA and QALSODY, both commercialized by Biogen. In addition, older assets such as TEGSEDI and WAYLIVRA remain available in selected international markets. From a competitive standpoint, Ionis occupies a differentiated niche at the intersection of rare disease, neurology, cardiovascular risk, and RNA therapeutics. Its competitive moat is not scale in the traditional pharma sense, but rather scientific depth, platform leadership, and a growing ability to translate research assets into commercial franchises. For investors, the company increasingly looks like a transition story: from a long-duration R&D organization into a more integrated commercial-stage biotech with a more visible earnings trajectory. Geographically, the United States remains the company’s most important market, but Ionis also has approved products and commercial arrangements across Europe, Canada, and other regions through partners. Recent catalysts have been meaningful. In 2026, Ionis highlighted strong momentum from the U.S. launches of TRYNGOLZA and DAWNZERA, while also advancing late-stage and regulatory programs such as zilganersen for Alexander disease and the potential broader commercialization of olezarsen in severe hypertriglyceridemia. The company has also emphasized improving financial momentum, supported by product sales, royalties, and collaboration revenue, which is important for investors assessing the durability of its growth story.